Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 966-973

  Kim, Myong Jin ^a   Nafziger, Anne N ^a,b   Zhang, Yanhua ^c   Sellers, Edward M ^c,d   Gaedigk, Andrea ^e   Bertino Jr , Joseph S ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b University of Toronto ^*  (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

CYP2C19; Dose dependency; Intrasubject variability; Omeprazole

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG METABOLISM; ENZYME POLYMORPHISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INDIVIDUALIZATION; MALE; NORMAL HUMAN; PHENOTYPE;

ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYLATION; MALE; MENSTRUAL CYCLE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE;

EID: 4143115578     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268910     Document Type: Article

References (23)

1. Birkett DJ, Andersson T, Miners JO. Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. Meth Enzymol. 1996;272:132-139.
2. Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monitor. 1990;12:415-416.
3. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther. 1995;57:662-669.
4. Chang M, Dahl ML, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995;5:358-363.
5. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther. 1996;60:138-144.
6. Streetman DS, Bleakley JF, Kim JS, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail." Clin Pharmacol Ther. 2000;68:375-383.
7. Kovacs P, Edwards DJ, Lalka D, et al. High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping. Ther Drug Monitor. 1999;21:526-531.
8. Kim MJ, Bertino JS Jr, Gaedigk A, et al. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther. 2002;72:192-199.
9. Lagerstrom PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chrom. 1984;309:347-356.
10. Goldstein JA, Blaisdell J: Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Meth Enzymol. 1996;272:210-217.
11. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther. 1996;59:647-653.
12. Edeki TI, Goldstein JA, de Morais SMF, et al. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans. Pharmacogenetics. 1996;6:357-360.
13. Zhang Y, Blouin RA, McNamara PJ, et al. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol. 1991;31:350-352.
14. Tamminga WJ, Wemer J, Oosterhuis B, et al. Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intraindividual reproducibility and occurrence of adverse events. Br J Clin Pharmacol. 2001;51:471-474.
15. Setiabudy R, Chiba K, Kusaka M, et al. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern oriental subjects. Br J Clin Pharmacol. 1992;33:665-666.
16. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989; 43:53-76.
17. Vinayek R, Amantea MA, Maton PN, et al. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology. 1991;101:138-147.
18. Hagg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol. 2001;51:169-173.
19. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther. 2000;68:151-159.
20. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch health volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55:177-184.
21. Shelepova T, Nafziger AN, Victory J, et al. Effect of oral contraceptives on drug metabolizing enzymes as measured by the validated Cooperstown 5+1 cocktail. Clin Pharmacol Ther. 2003;73:49.
22. Yin OQP, Tomlinson B, Chow AHL, et al. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol. 2004;44:582-589.
23. Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther. 1998;64: 391-401.